Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322770 | 0.91 | F2 (0.56) | F2TPSAB1CPN1CPB2EED | |
| SCHEMBL7391125 | 0.91 | F2 (0.56) | F2TPSAB1CPN1CPB2EED | |
| Hydrochloric Acid SCHEMBL9003170 | 0.90 | F2 (0.56) | F2TPSAB1CPN1CPB2 | |
| SCHEMBL24322551 | 0.86 | F2 (0.59) | F2TPSAB1CPN1CPB2 | |
| SCHEMBL24323889 | 0.81 | F2 (0.61) | F2TPSAB1 | |
| SCHEMBL24322784 | 0.77 | F2 (0.62) | F2TPSAB1CPN1CPB2 | |
| SCHEMBL24322712 | 0.76 | F2 (0.52) | F2TPSAB1CPN1CPB2EED | |
| SCHEMBL24324301 | 0.76 | F2 (0.43) | F2TPSAB1CPN1CPB2 | |
| SCHEMBL7390858 | 0.76 | F2 (0.43) | F2TPSAB1CPN1CPB2 | |
| Hydrochloric Acid SCHEMBL9002889 | 0.76 | F2 (0.44) | F2TPSAB1CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | F2 3514/4885TPSAB1 449/4885CTSS 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.